LINARES 5 MG 10'S

About

Linagliptin is an oral antidiabetic medication that belongs to the dipeptidyl peptidase-4 (DPP-4) inhibitor class. Its mechanism of action involves increasing the circulating levels of incretin hormones, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These natural hormones are released from the intestine throughout the day, with levels rising significantly after meals. By inhibiting DPP-4, linagliptin prolongs the activity of these incretins, which in turn enhances glucose-dependent insulin secretion from pancreatic beta cells and suppresses inappropriate glucagon secretion from pancreatic alpha cells. This leads to improved glycemic control by effectively lowering both fasting and postprandial blood glucose concentrations in adults with type 2 diabetes mellitus. A notable advantage of linagliptin is its primary excretion via the enterohepatic system, meaning it typically requires no dose adjustment in patients with renal impairment, simplifying its use in a broad patient population.

Uses

• Management of type 2 diabetes mellitus.
• Improvement of glycemic control.
• As monotherapy or in combination with other antidiabetics.
• When diet and exercise alone are insufficient.

Directions For Use

Take one tablet orally once daily, with or without food, as prescribed by your doctor. Swallow the tablet whole with a glass of water.

Benefits

• Effective blood sugar control.
• Low risk of hypoglycemia (when used alone).
• Weight-neutral effect.
• No dose adjustment needed for kidney impairment.
• Can be used with other antidiabetic agents.
• Improved pancreatic beta-cell function.

Side Effects

• Nasopharyngitis
• Cough
• Diarrhea
• Headache
• Hypoglycemia (when combined with sulfonylurea/insulin)
• Pancreatitis (rare)
• Joint pain (arthralgia)
• Skin rash
• Muscle pain (myalgia)
• Hypersensitivity reactions
• Bullous pemphigoid (rare)
• Upper respiratory tract infection

Safety Measures

• Alcohol - Moderate alcohol consumption is generally acceptable, but excessive intake should be avoided as it can affect blood sugar levels.
• Pregnancy - Not recommended during pregnancy due to insufficient data on human safety. Use only if potential benefit justifies the potential risk to the fetus.
• Breastfeeding - It is unknown if linagliptin is excreted in human milk. A decision should be made whether to discontinue nursing or discontinue the drug.
• Liver - No dose adjustment is required for patients with hepatic impairment. However, caution is advised in severe cases.
• Kidney - No dose adjustment is required for patients with renal impairment, including end-stage renal disease.
• Lung - No specific contraindications or safety concerns directly related to lung conditions.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.